Shukra Pharmaceuticals manufactures and markets pharmaceutical formulations, including antibiotics and chronic care medications, for both the Indian domestic market and various international export territories.
The company operates in a highly fragmented generic drug market with no evidence of durable pricing power, as reflected in volatile margins and an average ROCE of only 10%. While they hold WHO-GMP certifications, these are standard regulatory requirements rather than a competitive advantage that prevents commoditization.
Management has focused on internal reinvestment and debt reduction, maintaining a very low debt-to-equity ratio. However, the low cash conversion ratio suggests significant capital is tied up in working capital, particularly receivables and inventory, rather than generating high returns for shareholders.
The investment collapsed as the company's poor cash conversion finally strangled operations. While revenue appeared to grow, the capital was perpetually trapped in uncollected receivables and inventory, eventually leading to a liquidity crisis. The pattern of interest-free loans to related parties, which was already visible, expanded until it became clear that shareholder capital was being treated as a private piggy bank for insiders. When regulatory bodies finally enforced penalties for the chronic non-compliance with dividend transfers and reporting standards, the lack of a competitive moat left the company unable to pass on costs, resulting in a permanent impairment of capital.
RichFakir rates Shukra Pharmaceuticals Ltd's business quality as poor — 38/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shukra Pharmaceuticals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shukra Pharmaceuticals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shukra Pharmaceuticals Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →